More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$484017432
EPS
-3.21
P/E ratio
--
Price to sales
3.05
Dividend yield
--
Beta
1.238543
Previous close
$7.64
Today's open
$7.59
Day's range
$7.30 - $7.82
52 week range
$5.46 - $16.19
show more
CEO
Curran Simpson
Employees
371
Headquarters
Rockville, MD
Exchange
Nasdaq Global Select
Shares outstanding
66122600
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 13, 2026

REGENXBIO Q3 Earnings Call Highlights
REGENXBIO NASDAQ: RGNX is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company's third-quarter earnings call.
MarketBeat • Nov 6, 2026

Regenxbio: 2 Major Catalysts Could Change The Investment Case
Regenxbio Inc. is Buy-rated, with upcoming ATMOSPHERE and ASCENT readouts and RGX-202 regulatory milestones as key near-term catalysts. RGNX faces a structural revenue headwind from ZOLGENSMA royalty expiration, with new assets like ITVISMA and external funding supporting liquidity. Pivotal wet AMD Phase III data for sura-vec in 4Q26 and an RGX-202 BLA submission in 1Q27 are critical for future valuation.
Seeking Alpha • Nov 6, 2026

REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m. ET ROCKVILLE, Md.
PRNewsWire • Nov 5, 2026

Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to a loss of $1.2 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 4, 2026

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
Zacks Investment Research • Nov 4, 2026

REGENXBIO to Participate in Stifel 2026 Healthcare Conference
ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.
PRNewsWire • Nov 3, 2026

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.
PRNewsWire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell REGENXBIO Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.